MedTrace Logo

FDG (Fluorodeoxyglucose) Findings After COVID-19 Vaccination

NCT05270967 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 129

Last updated 2022-03-08

No results posted yet for this study

Summary

It is important to evaluate the vaccine-related metabolic changes on FDG PET/CT to avoid confusing results. The investigators aimed to assess the frequency and intensity of regional and systemic metabolic PET/CT changes of patients who received the mRNA-based COVID-19 vaccine (BNT162b2-Pfizer/BioNTech) and to analyze possible factors affecting these changes.

Conditions

Interventions

DIAGNOSTIC_TEST

F-18 FDG PET/CT imaging

Oncological imaging

BIOLOGICAL

Pfizer/biontech mRNA vaccine

COVID-19 vaccine

Sponsors & Collaborators

  • Kocaeli University

    lead OTHER

Principal Investigators

  • Serkan Isgoren, Ass prof · Kocaeli University School of Medicine

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-29
Primary Completion
2022-01-10
Completion
2022-01-10
FDA Drug
Yes

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05270967 on ClinicalTrials.gov